PATENT CLAIM ANALYSIS

Application Number: 16125124
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "319000"]

Abstract:
The disclosure generally relates to pharmaceutical compositions including a benzhydrylsulfinylacetamide antidepressant and an amount of sodium chloride effective to increase a mean arterial blood pressure of a subject and methods for ameliorating symptoms of dementia including forms of dementia diagnosed as Alzheimer's disease and side-effects associated with the administration of cognition effecting pharmaceuticals.

Claim (Index 15):
A method for alleviating side-effects associated with the administration of cognition effecting pharmaceuticals comprising:\n administering a benzhydrylsulfinylacetamide wakefulness promoting agent and an amount of sodium chloride to a subject having a side-effect from a cognition effecting pharmaceutical; wherein the amount of sodium chloride is effective to increase mean arterial blood pressure of the subject.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15409775', '15409655', '16090142', '12689957', '16119439']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6755383286272751
- 35 USC 102 Novelty (BERT): 0.495454416030362
- Combined Prediction Score: 0.6575299373675838
- Mean Citation Score: 188.03500000000005
- Max Citation Score: 198.47554
- Similarity Product: 139.49672014713406

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test